115956-13-3

Usage

Uses

Used in Chemotherapy-Induced Nausea and Vomiting:
Dolasetron mesylate is used as an antiemetic for the prevention of nausea and vomiting in chemotherapy patients. It works by blocking the 5-HT3 receptors, which are responsible for the sensation of nausea and vomiting during chemotherapy treatment. In a clinical study with 164 cancer patients treated with Dolasetron mesylate prior to Cisplatin, single doses of 10-50 mg achieved major control of nausea and emesis in 73% of subjects and were well tolerated.
Used in Antidepressant Treatment:
Dolasetron mesylate is also used as an antidepressant, helping to alleviate symptoms of depression by modulating the serotonin levels in the brain. As a 5-HT3 receptor antagonist, it can potentially improve mood and reduce the severity of depressive symptoms.
Used in Pharmaceutical Research:
Dolasetron mesylate acts as a specific serotonin (5HT3) receptor antagonist and has been used in pharmaceutical research to study the role of 5-HT3 receptors in various conditions, including nausea, vomiting, and depression. This research can lead to the development of new drugs and therapies targeting these receptors for improved treatment options.

Antiemetics

Vomiting is an extremely complex reflex activity, involving a variety of neurotransmitters. Antiemetics produce antiemetic effect by blocking different receptors. 5-HT3 receptor blocking drugs can selectively block the 5-HT3 receptors of the central and vagal afferent fibers , resulting in strong antiemetic effect. For vomiting caused by anticancer drugs, its antiemetic effect is quick and powerful, but it is invalid in vomiting caused by motion sickness and apomorphine.It is clinically used for chemotherapy, radiotherapy-induced nausea and vomiting. Clinical application includes ondansetron (Zofran), granisetron , dolasetron mesylate, dolasetron and tropisetron , its clinically equivalent doses are 8mg, 3mg, 100mg and 5mg. Dolasetron mesylate is an anti-emetic drug, it is originally developed by the German company Hoechst Marion Roussel , it is developed as a selective serotonin (5-HT3) receptor antagonist, its acting is similar to Ondansetron and granisetron. The oral administration and intravenous injections of the product are effective for preventing and treating nausea and vomiting caused by cancer chemotherapy. 5-HT3 receptor antagonist in combination with dexamethasone or other corticosteroids is the most effective combined therapy for the prevention of acute vomiting caused by cancer chemotherapy . US FDA suggests that the product can also be used for the prevention and treatment of postoperative nausea or vomiting. Dolasetron mesylate is rapidly metabolized to hydrogenated dolasetron in plasma and liver , the active metabolite in the liver is further metabolized by the CYP2D6 and CYP3A , then it is excreted with urine and feces, the half-life of the product is about 8h.

Clinical Study

Antiemetic effect of this product is stronger than any other 5-HT3 receptor antagonists. Randomized trial of 609 cases of patients with cisplatin showed that single intravenous dose of the product 1.8mg/kg for the prevention of acute emesis in full force is 49%, effective rate of the product 2.4 mg/kg intravenously is 46%,effective rate of intravenous ondansetron 32mg is 50%. Antiemetic effect of this product intravenous is equal to granisetron . A single oral dose of 100mg of this product in patients adopting moderate antiemetic measures, can completely prevent about 60% of patients vomiting. The above information is edited by the lookchem of Tian Ye.

Adverse reactions and precautions

Adverse reactions of dolasetron mesylate are similar to Ondansetron and granisetron,including a slight headache, dizziness, dose-related transient ECG changes may occur, clinical symptoms are usually not obvious , they can be recovered by themselves. An increased incidence of hepatocellular adenoma and carcinoma will occur in mouse using this for 2 years. Dolasetron is not appropriate used with drugs that affect the heart function (QT prolongation) , such as astemizole, terfenadine, cisapride, pentamidine, tricyclic antidepressants (eg Amitriptyline ), phenothiazines drugs (such as chlorpromazine), pimozide, sparfloxacin, antiarrhythmic drugs (eg quinidine, procainamide, amiodarone, bepridil, A atenolol). It is also not compatible with diuretics, anthracycline anticancer drug (such as idarubicin, doxorubicin, daunorubicin), cimetidine, rifamycins (eg, rifampin), or phenytoin carbamazepine. Before using this drug, we should pay attention to history, including allergies (especially drug allergies), heart disease, electrolyte imbalance such as low potassium or low magnesium. Because the drug can cause dizziness, when engaged in tasks requiring alertness (such as driving), please use with caution. Pregnant women, lactating women use with caution.

Originator

Hoechst Marion Roussel (Germany)

Veterinary Drugs and Treatments

Dolasetron may be effective in treating severe nausea and vomiting in dogs and cats, particularly if caused by cancer chemotherapy drugs. Because it is given once a day, the injectable form of dolasetron is often preferred over ondansetron, a similarly effective antiemetic. However, for oral use in small animals, dolasetron tablets are too large (50 and 100 mg) to be practically administered.

InChI:InChI=1/C19H20N2O3.CH4O3S.H2O/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17;1-5(2,3)4;/h1-4,9,11-14,20H,5-8,10H2;1H3,(H,2,3,4);1H2/t11-,12+,13-,14-;;

Upstream product

• 75-75-2 methanesulfonic acid 
• 115956-12-2 dolasetron 
• 59496-25-2 Indole-3-carbonyl chloride 
• 143343-85-5 endo-5-hydroxy-8-azatricyclo[5.3.1.0³,⁸]-undecan-10-one 
• 115956-07-5 endo-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one 
• 771-50-6 1H-indole-3-carboxylic acid 
• 115956-12-2 endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one 
• 115956-12-2 endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one 
• 115956-07-5 endo-hexahydro-8-hydroxy-2.6-methano-2H-quinolizin-3(4H)-one 
• 115956-12-2 dolasetron 

Related news

CdS nanocrystals as fluorescent probe for detection of Dolasetron mesylate (cas 115956-13-3) in aqueous solution: Application to biomedical analysis07/11/2019

A simple and straightforward method for the determination of dolasetron mesylate (DM) in aqueous solution was developed based on the fluorescence quenching of 3-Mercaptopropionic acid (MPA) capped CdS quantum dots (QDs). The structure, morphology, and optical properties of synthesized QDs were c...detailed

Relevant academic research and scientific papers

Dolasetron N-oxide, preparation method and application thereof

The invention relates to a dolasetron N-oxide with a structure shown in a formula (I) or a salt thereof, and a preparation method and application of the compound, wherein the compound has a relatively strong inhibition effect on kinases Lyn and MST1, and can be used as an antitumor drug.

Dolasetron oxide and preparation method and application thereof

The invention relates to dolasetron oxide with a structure shown as a formula (I) or salt thereof, and a preparation method and application of the dolasetron oxide, and the dolasetron oxide has a strong inhibition effect on kinase Lyn and MST1, and can be used as an antitumor drug.

Dolasetron mesylate crystal form and preparation method

The invention provides a dolasetron mesylate crystal form. The molecular structural formula is represented in the description. The crystal form is a white powdery crystal, molecular composition is C19H20N2O3.CH3SO3H.H2O, a reflection angle 2 theta of X-ray powder diffraction of the crystal form has characteristic peaks at 11.8 degrees, 12.1 degrees, 15.1 degrees, 15.4 degrees, 22.9 degrees, 26.6 degrees, 29.9 degrees and 30.1 degrees, and differential scanning calorimetry shows that three absorption peaks exist at 150 DEG C, 164 DEG C and 260 DEG C. According to the dolasetron mesylate crystalform, product purity is high, few single impurities are contained, and heat stability of the crystal form is good. The invention further provides a preparation method of the dolasetron mesylate crystal form.

Polymorphs of Dolasetron base and process for preparation thereof

The present invention provides polymorphic forms of dolasetron base and methods for their use and preparation.

INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON

The present invention relates to intermediates useful in the synthesis of Dolasetron and synthetic precursors thereof, as well as to processes for obtaining them. In addition, it refers to the hydrochloric salt of Dolasetron and polymorphic forms of Dolasetron and precursors thereof.

Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof

The present disclosure relates to a process for the preparation of endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one or Dolasetron base. It also discloses a process for the preparation of endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one mesylate or Dolasetron mesylate. Further, the present disclosure relates to a process for producing Form I of Dolasetron base, and to the novel crystalline polymorphs, Form II, III, IV and V of Dolasetron base and industrial processes for producing them.

METHOD FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND, SYNTHESIS INTERMEDIATES THEREOF AND METHODS FOR OBTAINING THEM

The present invention relates to a method for obtaining Dolasetron that comprises: a) Esterification of the alcohol of formula (IV) with indole-3-carboxylic acid (compound (III)) or a reactive derivative thereof, to give a compound of formula (V), followed by step b) which includes Dieckmann reaction of the intermediate (V), by reaction with a strong organic or inorganic base, to give the intermediate (VI), and step c) which comprises dealcoxycarbonylation of the intermediate (VI) to give Dolasetron base and, if desired, a pharmaceutically acceptable salt thereof, hydrates or solvates of the base of said salt. The invention also relates to the intermediates (V) and (VI), and methods for obtaining them. With the method of the present invention Dolasetron is obtained at industrial scale with good yields, with decreased use of reactants and solvents, while said method is also of greater atomic efficiency.

METHOD FOR PREPARING HEXAHYDRO-8-HYDROXY-2,6-METHANO-2H-CHINOLIZIN-3(4H)-ONE ESTERS

The invention concerns a method for preparing optionally substituted 3-indolcarboxylic acid esters, with hexahydro-8-hydroxy-2,6-methano-2H-chinolizin-3(4H)-one. The invention is characterized in that the optionally substituted 3-indolcarboxylic acid is c

Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds

The present invention is directed to a group of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(3H)-ones and related compounds. The compounds are prepared from the appropriate carboxylic acids and alcohols by standard procedures or, where steric factors are significant, a new process which makes use of heavy metal salts of super acids can be used. The compounds involved are useful in the treatment of migraine and similar disorders and in cytotoxic drug-induced vomiting.